Separately, well-established evidence has identified that obesity contributes to decreases in PSA levels by increasing circulating plasma volumes (i.e., hemodilution of PSA), yet increases risk of aggressive prostate cancer (Bañez et al., 2007, Freedland and Aronson, 2004). Here, KLK3 is linked to obesity due to melanocortin 4 receptor deficiency.